|
 |
AlphaganThis page contains recent news articles, when available, and an overview of Alphagan but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Alphagan (when available) Brimonidine significantly lowers intraocular pressure with minimal effects on cardiovascular and pulmonary parameters. It lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow. For the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Mechanism Of Action: Brimonidine is an alpha adrenergic receptor agonist. It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that Brimonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. News Articles on Brimonidine NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont® - Dec 13, 2009 Inc. where he played a major role in the development of a number of high selling dermal and ophthalmic drugs such as Alphagan®, Lumigan® for glaucoma, ... PR-USA.net (press release) Allergan Victory in ALPHAGAN® P Patent Infringemet Suit - Oct 27, 2009 The defendants had been seeking permission to market generic versions of Allergan's drugs ALPHAGAN® P, which is indicated for the lowering of intraocular ... IPWatchdog.com Allergan Q3 2009 Earnings Call Transcript - Oct 29, 2009 In Europe, ALPHAGAN has been affected by the launch of generics in the main market but it is being offset by strong COMBIGAN growth. ... Seeking Alpha (blog) Allergan Claims Victory in Patent Suit Over Generics - Nov 7, 2009 A judge ruled that all five of Allergan's patents for Alphagan P are valid and enforceable, according to Allergan. Alphagan P works by lowering eye pressure ... Orange County Business Journal Allergan wins ruling in patent case against 2 drugmakers - Oct 25, 2009 TEL AVIV (MarketWatch) -- Allergan Inc. won a ruling in federal court that its patents on Alphagan, which lowers pressure in ... MarketWatch Health care reform needs to extend to drug prices - Oct 29, 2009 A study reported in the American Journal of Ophthalmology showed the yearly cost in 2006 for a patient on three brand-name eyedrops (Xalatan, Alphagan P and ... Modesto Bee Allergan wins patent infringement suit over generic versions of brimonidine - Oct 30, 2009 A US district court ruled in favor of Allergan in a patent infringement suit filed against companies aiming to market generic versions of Alphagan, ... OSN SuperSite Allergan wins brimonidine patent infringement case - Nov 4, 2009 ...purported generic versions of the company's formulations of brimonidine tartrate 0.1% and 0.15% (Alphagan P) for ocular hypertension and glaucoma. ... ModernMedicine Lumigan X EU Committee Recomendation - Oct 28, 2009 Allergan's ill-advised manipulation of concentrations with their Alphagan (brimonidine) product by bringing out Alphagan-P did not take market share from ... Gerson Lehrman Group The New Look Technorati and Technorati Authority - Oct 26, 2009 ...respect to ALPHAGAN® P, which is indicated for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ... IPWatchdog.com Alcon Posts 5.9 Percent Sales Growth for Third Quarter - Oct 27, 2009 On October 2, 2009, the company launched brimonidine 0.15% in the United States which is the only non-branded version of Alphagan® P 0.15% on the market. ... Reuters Allergan Wins Patent Suit - Oct 26, 2009 Allergan said the defendants were looking to make generic versions of its ALPHAGAN P drug. Allergan said the court has ruled that all five patents owned by ... socalTech.com Alcon Posts 5.9 Percent Sales Growth for Third Quarter - Oct 27, 2009 On October 2, 2009, the company launched brimonidine 0.15% in the United States which is the only non-branded version of Alphagan® P 0.15% on the market. ... istockAnalyst.com (press release) Stocks May Attempt To Rebound Even As Apprehensions Remain - RTTNews Daily ... - Oct 26, 2009 ...its patent infringement lawsuit against Exela PharmSci and Apotex, which were seeking to market purported generic versions of Allergan's drug ALPHAGAN. ... Trading Markets (press release) Brand Names/Synonyms: Alphagan is also known by the following brand names and/or synonymsAlphagan; Alphagan P; Brimonidine; Brimonidine Tartrate; Bromoxidine; CHEMBANK1623 Drug Category: Alphagan is categorized under the following by the FDA: Antihypertensive Agents; EENT Drugs; ATC:S01EA05 Dosage Forms: 0.2% solution Absorption: Minimal systemic absorption occurs after ocular insertion. Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
